Show the full website


Lundbeck plans to succeed with migraine drug – Teva failed

Lundbeck's ambitions for the migraine drug Vyepti go beyond what is reflected in the current FDA approval, EVP Johan Luthmann tells MedWatch.

Foto: Lundbeck / PR

Later this year, Lundbeck is planning to start a clinical trial to take the company's great venture Vyepti to new business areas, says Lundbeck's Executive Vice President and Head of Research and Development Johan Luthmann to MedWatch.

Vyepti adheres to the class of CGRP (Calcitonin Gene-Related Peptide, -ed.) drugs that are currently progressing triumphantly in migraine treatments, and Lundbeck plans to exploit this mechanism to the fullest.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Receive newsletter from MedWatch today

NB: Subscribing to the newsletter is free.

More from MedWatch


See all jobs